The FDA granted investigational drug clearance to HG202, a CRISPR/Cas13Y RNA-editing therapy for neovascular age-related macular degeneration, according to a press release from HuidaGene. According to the release, HG202 is the first CRISPR/Cas13Y RNA-targeting therapy in clinical development as well as the only clinical-stage CRISPR RNA-editing therapy for AMD.
New research sheds light on how the dry eye medication lifitegrast works beyond the ocular surface, targeting the underlying immune system to provide relief for…
This cohort study investigates the outcomes of patients with and without age-related macular degeneration (AMD) who were taking curcuma-based nutritional supplements.
The 2024 GOLD International COPD Conference will be held Nov. 11 and 12 in Philadelphia and online, featuring presentations from various speakers on important topics…
PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of…
BOSTON — A multimodal fusion model outperformed transthoracic echocardiography in identifying pulmonary hypertension, according to a study presented at the CHEST Annual Meeting.This model could…
Ex-smokers with a light lifetime smoking burden had a CVD risk shortly after quitting similar to those who have never smoked, results from a cohort…
In this episode of CRST: The Podcast, John A. Hovanesian, MD, hosts Emily Schehlein, MD, to explore actionable steps for reducing waste in cataract surgery. Dr.…
We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD,…
Former five-time Olympian, Gail Devers, writes about how thyroid eye disease (TED) put her life and running career on hold
Patients with systemic sclerosis demonstrate lower bone mineral density compared with the general population, with significant differences reported in women aged younger than 45 years,…
